TY  - JOUR
AU  - Jurišević, Milena
AU  - Radosavljević, Gordana
AU  - Arsenijević, Aleksandar
AU  - Milovanović, Marija
AU  - Gajović, Nevena
AU  - Đorđević, Dragana S.
AU  - Milovanović, Jelena
AU  - Stojanović, Bojana
AU  - Ilić, Aleksandar
AU  - Sabo, Tibor
AU  - Kanjevac, Tatjana
PY  - 2016
UR  - https://cherry.chem.bg.ac.rs/handle/123456789/216
AB  - e design of platinum based drugs is not a new field of interest. Platinum complexes are widely used as anticancer agents and currently, approximately 30 platinum(II) and platinum(IV) entered into some of the phases of clinical trials. A special place in today’s research belongs to platinum complexes with diammine ligands. A large number of edda (ethylenediamine- N, N’-diacetate)-type ligands and their corresponding metal complexes has been successfully synthesized. is article summarizes recent progress in research on edda-type-platinum complexes. Some of these agents achieves better effect compared to the gold standard (cisplatin). It has been shown that there is a possible relationship between the length of the ligand ester group carbon chain and its cytotoxic effect. In most cases the longer the ester chain is the greater is the antitumor activity. Of particular interest are the noticeable effects of some new platinum compound with edda-type ligand on cell lines that are known to have a high level of cisplatin-resistance. Exanimate complexes appear to have a diff erent mode of mechanism of action compared with cisplatin which includes apoptotic and necrotic cell death. ere are indications that further investigations of these compounds may be very useful in overcoming the problems associated global cancer statistic. © 2016, University of Kragujevac, Faculty of Science. All rights reserved.
AB  - Kompleski platine koriste se kao osnova za dizajn novih lekova. Oni su u širokoj upotrebi kao antitumorski agensi i do danas je oko 30 komplesa platine(II) i platine(IV) u nekoj od faza kliničkog ispitivanja. Posebno mesto u današnjim istaživanjima zauzimaju kompleksi metala sa edda ligandima. Uspešno je sintetisan veliki broj novih edda liganda i odgovarajućih kompleksa. Neki od ovih agensa pokazuju bolju aktivnost od zlatnog standarda, cisplatine. Pokazano je da postoji moguća veza između dužine ugljovodiničnog lanca estraske grupe liganda i citotoksičnog efekta. U većini slučajeva dužina lanca direktno korelira sa antitumorskom aktivnošću. Zabeležena je efikasnija citotoksicna aktivnost određenih kompleska platine sa edda ligandima na ćelijskim linijama tumora koji pokazuju odgovarajući stepen rezistencije na cisplatinu. Ispitivani komleksi imaju različit mehanizam dejstva od cisplatine, koji uključuje elemente nekrotične i programirane ćelijske smrti. Postoje nagoveštaji da dalja istraživanja ovih agensa mogu biti značajna za prevazilaženje globalnog problema sa kojim se svet danas suočava, a koji se odnosi na stalni porast osoba obolelih od karcinoma.
T2  - Serbian Journal of Experimental and Clinical Research (ranije: Medicus)
T1  - Platinum complexes with edda ethylenediamine n, n diacetate ligands as potential anticancer agents [Kompleksi platine sa edda etilendiamin N, N’ diacetat ligandima kao potencijalni antitumorski agensi]
T1  - Kompleksi platine sa edda (etilendiamin-N, N'-diacetat) ligandima kao potencijalni antitumorski agensi
VL  - 17
IS  - 4
SP  - 285
EP  - 295
DO  - 10.1515/SJECR-2016-0042
ER  - 

@article{
author = "Jurišević, Milena and Radosavljević, Gordana and Arsenijević, Aleksandar and Milovanović, Marija and Gajović, Nevena and Đorđević, Dragana S. and Milovanović, Jelena and Stojanović, Bojana and Ilić, Aleksandar and Sabo, Tibor and Kanjevac, Tatjana",
year = "2016",
abstract = "e design of platinum based drugs is not a new field of interest. Platinum complexes are widely used as anticancer agents and currently, approximately 30 platinum(II) and platinum(IV) entered into some of the phases of clinical trials. A special place in today’s research belongs to platinum complexes with diammine ligands. A large number of edda (ethylenediamine- N, N’-diacetate)-type ligands and their corresponding metal complexes has been successfully synthesized. is article summarizes recent progress in research on edda-type-platinum complexes. Some of these agents achieves better effect compared to the gold standard (cisplatin). It has been shown that there is a possible relationship between the length of the ligand ester group carbon chain and its cytotoxic effect. In most cases the longer the ester chain is the greater is the antitumor activity. Of particular interest are the noticeable effects of some new platinum compound with edda-type ligand on cell lines that are known to have a high level of cisplatin-resistance. Exanimate complexes appear to have a diff erent mode of mechanism of action compared with cisplatin which includes apoptotic and necrotic cell death. ere are indications that further investigations of these compounds may be very useful in overcoming the problems associated global cancer statistic. © 2016, University of Kragujevac, Faculty of Science. All rights reserved., Kompleski platine koriste se kao osnova za dizajn novih lekova. Oni su u širokoj upotrebi kao antitumorski agensi i do danas je oko 30 komplesa platine(II) i platine(IV) u nekoj od faza kliničkog ispitivanja. Posebno mesto u današnjim istaživanjima zauzimaju kompleksi metala sa edda ligandima. Uspešno je sintetisan veliki broj novih edda liganda i odgovarajućih kompleksa. Neki od ovih agensa pokazuju bolju aktivnost od zlatnog standarda, cisplatine. Pokazano je da postoji moguća veza između dužine ugljovodiničnog lanca estraske grupe liganda i citotoksičnog efekta. U većini slučajeva dužina lanca direktno korelira sa antitumorskom aktivnošću. Zabeležena je efikasnija citotoksicna aktivnost određenih kompleska platine sa edda ligandima na ćelijskim linijama tumora koji pokazuju odgovarajući stepen rezistencije na cisplatinu. Ispitivani komleksi imaju različit mehanizam dejstva od cisplatine, koji uključuje elemente nekrotične i programirane ćelijske smrti. Postoje nagoveštaji da dalja istraživanja ovih agensa mogu biti značajna za prevazilaženje globalnog problema sa kojim se svet danas suočava, a koji se odnosi na stalni porast osoba obolelih od karcinoma.",
journal = "Serbian Journal of Experimental and Clinical Research (ranije: Medicus)",
title = "Platinum complexes with edda ethylenediamine n, n diacetate ligands as potential anticancer agents [Kompleksi platine sa edda etilendiamin N, N’ diacetat ligandima kao potencijalni antitumorski agensi], Kompleksi platine sa edda (etilendiamin-N, N'-diacetat) ligandima kao potencijalni antitumorski agensi",
volume = "17",
number = "4",
pages = "285-295",
doi = "10.1515/SJECR-2016-0042"
}

Jurišević, M., Radosavljević, G., Arsenijević, A., Milovanović, M., Gajović, N., Đorđević, D. S., Milovanović, J., Stojanović, B., Ilić, A., Sabo, T.,& Kanjevac, T.. (2016). Platinum complexes with edda ethylenediamine n, n diacetate ligands as potential anticancer agents [Kompleksi platine sa edda etilendiamin N, N’ diacetat ligandima kao potencijalni antitumorski agensi]. in Serbian Journal of Experimental and Clinical Research (ranije: Medicus), 17(4), 285-295.
https://doi.org/10.1515/SJECR-2016-0042

Jurišević M, Radosavljević G, Arsenijević A, Milovanović M, Gajović N, Đorđević DS, Milovanović J, Stojanović B, Ilić A, Sabo T, Kanjevac T. Platinum complexes with edda ethylenediamine n, n diacetate ligands as potential anticancer agents [Kompleksi platine sa edda etilendiamin N, N’ diacetat ligandima kao potencijalni antitumorski agensi]. in Serbian Journal of Experimental and Clinical Research (ranije: Medicus). 2016;17(4):285-295.
doi:10.1515/SJECR-2016-0042 .

Jurišević, Milena, Radosavljević, Gordana, Arsenijević, Aleksandar, Milovanović, Marija, Gajović, Nevena, Đorđević, Dragana S., Milovanović, Jelena, Stojanović, Bojana, Ilić, Aleksandar, Sabo, Tibor, Kanjevac, Tatjana, "Platinum complexes with edda ethylenediamine n, n diacetate ligands as potential anticancer agents [Kompleksi platine sa edda etilendiamin N, N’ diacetat ligandima kao potencijalni antitumorski agensi]" in Serbian Journal of Experimental and Clinical Research (ranije: Medicus), 17, no. 4 (2016):285-295,
https://doi.org/10.1515/SJECR-2016-0042 . .